Drug profile · INN
ecallantide
KALBITOR
ecallantide (KALBITOR) is a plasma kallikrein inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — ecallantide
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
ecallantide (KALBITOR) is a plasma kallikrein inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Plasma kallikrein inhibitor
Primary target: Plasma kallikrein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ecallantide?
ecallantide (KALBITOR) is a plasma kallikrein inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for ecallantide?
KALBITOR is a marketed brand name for ecallantide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ecallantide?
ecallantide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.